Immunitybio is trading 7.3% up at $7.33 in after-hours sessions, rebounding from recent weakness despite a lack of fresh company-specific news.
- No earnings releases, FDA updates, or headlines have been tied directly to the move.
- The price action contrasts with broadly weaker major indices, potentially reflecting technical buying or low-liquidity volatility.